Lisata Therapeutics Inc (LTS:0HS8)
$ 3.255 0 (0%) Market Cap: 28.95 Mil Enterprise Value: -14.23 Mil PE Ratio: 0 PB Ratio: 0.67 GF Score: 37/100

Q2 2019 Caladrius Biosciences Inc Earnings Call Transcript

Aug 08, 2019 / 08:30PM GMT
Release Date Price: $44.25
Operator

Welcome to the Caladrius Biosciences Second Quarter 2019 Financial Results and Business Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, Thursday, August 08, 2019. I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

John D. Menditto
Caladrius Biosciences, Inc. - VP of IR & Corporate Communications

Good afternoon. And thank you all for participating in today's call. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; and Joseph Talamo, Chief Financial Officer.

Earlier today we issued a news release announcing our 2019 second quarter financial results. If you have not received this news release or if you would like to be added to the company's e-mail distribution list, please e-mail me at [email protected].

Before we begin, I will remind you that comments made by management during this conference call will contain forward-looking statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot